AU782188B2 - Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines - Google Patents

Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines Download PDF

Info

Publication number
AU782188B2
AU782188B2 AU59697/00A AU5969700A AU782188B2 AU 782188 B2 AU782188 B2 AU 782188B2 AU 59697/00 A AU59697/00 A AU 59697/00A AU 5969700 A AU5969700 A AU 5969700A AU 782188 B2 AU782188 B2 AU 782188B2
Authority
AU
Australia
Prior art keywords
carnitine
alkanoyl
acid
hmg
coa reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU59697/00A
Other languages
English (en)
Other versions
AU5969700A (en
Inventor
Arduino Arduini
Paolo Carminati
Alessandro Peschechera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/en
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU5969700A publication Critical patent/AU5969700A/en
Application granted granted Critical
Publication of AU782188B2 publication Critical patent/AU782188B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU59697/00A 1999-06-08 2000-06-05 Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines Ceased AU782188B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
US60/138008 1999-06-08
EP99830415 1999-06-30
EP99830415A EP1064943B1 (en) 1999-06-30 1999-06-30 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
PCT/EP2000/005091 WO2000074675A1 (en) 1999-06-08 2000-06-05 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Publications (2)

Publication Number Publication Date
AU5969700A AU5969700A (en) 2000-12-28
AU782188B2 true AU782188B2 (en) 2005-07-07

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59697/00A Ceased AU782188B2 (en) 1999-06-08 2000-06-05 Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines

Country Status (10)

Country Link
JP (1) JP2003501385A (enExample)
KR (1) KR100725263B1 (enExample)
AU (1) AU782188B2 (enExample)
CA (1) CA2375378C (enExample)
CZ (1) CZ20014218A3 (enExample)
HU (1) HUP0201597A3 (enExample)
MX (1) MXPA01012644A (enExample)
PL (1) PL197899B1 (enExample)
SK (1) SK285900B6 (enExample)
WO (1) WO2000074675A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104239A1 (en) * 2007-02-27 2008-09-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of type 2 diabetes
ES2546619T3 (es) * 2007-03-21 2015-09-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composición útil para la prevención de la diabetes tipo 2 y sus complicaciones en pacientes pre-diabéticos con resistencia a la insulina
KR101686917B1 (ko) * 2008-02-29 2016-12-15 바이오랩 세너스 팔마씨우티카 엘티디에이. 라세탐 및 카르니틴을 포함하는 약학 조성물 및 그의 제조방법
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001126A1 (en) * 1997-07-01 1999-01-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001126A1 (en) * 1997-07-01 1999-01-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Also Published As

Publication number Publication date
KR100725263B1 (ko) 2007-06-07
KR20020025066A (ko) 2002-04-03
SK285900B6 (sk) 2007-10-04
HUP0201597A2 (en) 2002-09-28
PL352106A1 (en) 2003-07-28
PL197899B1 (pl) 2008-05-30
CA2375378C (en) 2009-08-11
SK17152001A3 (sk) 2002-03-05
MXPA01012644A (es) 2002-07-22
JP2003501385A (ja) 2003-01-14
AU5969700A (en) 2000-12-28
HUP0201597A3 (en) 2003-04-28
WO2000074675A1 (en) 2000-12-14
CZ20014218A3 (cs) 2002-04-17
CA2375378A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
US5260305A (en) Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
CN1838949B (zh) 包含二甲双胍和他汀的组合的药物组合物
SK284142B6 (sk) Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
US6245800B1 (en) Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
WO2020099926A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
CA2007983C (en) Coenzyme q10 with hmg-coa reductase inhibitors
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
AU782188B2 (en) Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines
US9642860B2 (en) Combinations of corroles and statins
US11602510B2 (en) Agent for use in the treatment of dyslipidemia
EP1064943B1 (en) Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
WO2009100245A1 (en) Low dose hmg-coa reductase inhibitor with reduced side effects
CN113134086B (zh) 一种降血脂的药物组合物
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
US20050182106A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
EP1699448A2 (en) Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
Hamilton-Craig et al. Statin-fibrate combination therapy
NZ542505A (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT TO READ: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.